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Recently, an angiotensin inhibitor has been shown to upregulate the klotho mRNA level in 
chronic renal failure.  In addition, the administration of vitamin D has been reported to 
improve the mortality of patients with chronic renal failure.  In this study, we examined 
the effects of an angiotensin inhibitor and/or vitamin D on the progression of chronic renal 
failure by using male 5/6 nephrectomized (5/6Nx) spontaneously hypertensive rats.  Male 
5/6Nx spontaneously hypertensive rats were assigned to 4 groups as follows: 5/6Nx group, 
5/6Nx rats; Alf group, 5/6Nx rats administered alfacalcidol (0.2 μg/kg/day); Olm group, 
5/6Nx rats administered olmesartan (15 mg/kg/day); Alf + Olm group, 5/6Nx rats admin-
istered alfacalcidol (0.2 μg/kg/day) and olmesartan (15 mg/kg/day).  These drugs were 
administered for 12 weeks.  Systolic blood pressure in the Alf, Olm and Alf + Olm groups 
were significantly decreased relative to that in the 5/6Nx group during the 12-week experi-
mental period.  As a result, all treated groups showed renoprotection based on improve-
ment of the systolic blood pressure, urinary protein excretion and histological renal fibro-
sis.  Combination therapy of alfacalcidol and olmesartan was more effective than either al-
facalcidol or olmesartan alone.  Expression of klotho mRNA was significantly upregulated 
in the Alf + Olm group in comparison with in the 5/6Nx group.  Serum levels of fibroblast 
growth factor 23 in the Alf group and the Alf + Olm group were significantly higher than 
those in the 5/6Nx group and the Olm group.  In conclusion, the combination of Olm and 
Alf inhibited the progression of renal damage in the 5/6Nx group through the strong anti-
hypertensive effect as well as the upregulation of the klotho gene.  
Key words: angiotensin II receptor blocker; chronic renal failure; fibroblast growth factor 23; 
klotho gene; vitamin D
Abbreviations:  Alf group, group of alfacalcidol-administered 5/6Nx rats; Alf + Olm group, group of alfacalcidol- and olme-
sartan-administered 5/6Nx rats; ARB, angiotensin II receptor blocker; CRF, chronic renal failure; FGF23, fibroblast growth 
factor 23; IGS, index of glomerular sclerosis; Nx, nephrectomized; Olm group, group of olmesartan-administered 5/6Nx rats; 
TGF, transforming growth factor
It was discovered approximately a decade ago 
that a deletion of the klotho gene results in pheno-
types resembling those of human aging-associated 
disorders (arteriosclerosis, osteoporosis, ectopic 
calcification and skin atrophy, together with short 
life-span).  Transcripts of this gene are expressed 
predominantly in the kidney, choroids plexus and 
parathyroid gland (Kuro-o et al., 1997).  The com-
plication of chronic renal failure (CRF) closely 
resembles phenotypes seen in klotho mutants. 
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Therefore, the severe reduction of klotho expression 
might be related to the pathophysiology of CRF 
(Haruna et al., 2007).  Indeed, the expression of the 
klotho gene in the kidney of the nephrectomized 
(Nx) rats, a model of CRF in humans, was signifi-
cantly downregulated (Aizawa et al., 1998).  In ad-
dition, it is known that the production of klotho in 
the kidney of human CRF patients was markedly 
reduced (Koh et al., 2001).  Previously, we have 
shown that a renin-angiotensin system inhibitor 
such as angiotensin-converting enzyme inhibitor or 
angiotensin II receptor blocker (ARB) prevented the 
klotho mRNA downregulation in the 5/6Nx rats, 
indicating that renin-angiotensin system inhibitors 
have a renoprotective effect (Maeta et al., 2009).
 In klotho-deficient mice, the levels of serum 
P, Ca and active vitamin D [1,25(OH)2 vitamin D3] 
were elevated.  Ectopic calcification and vascular 
calcification in klotho-deficient mice might be due 
to elevated blood levels of Ca, P and active vitamin 
D.  Reduction of serum 1,25(OH)2 vitamin D3 con-
centration by dietary restriction resulted in allevia-
tion of most of the phenotypes (Tsujikawa et al., 
2003).
 In addition, there is a report that active vita-
min D therapy is a possible factor in the increased 
serum fibroblast growth factor 23 (FGF23) levels 
in chronic kidney disease (Nakanishi et al., 2005; 
Saito et al., 2005).  FGF23 was identified as an 
endocrine factor produced by bone with known 
functions to regulate urinary P excretion, as well 
as the production of 1,25(OH)2 vitamin D3 and 
parathyroid hormone (Kurosu et al., 2006).  Se-
rum FGF 23 levels were significantly elevated in 
chronic kidney disease patients in a close correla-
tion with serum creatinine (Komba and Fukagawa, 
2009).  Increased FGF 23 level appears to be inde-
pendently associated with mortality among patients 
undergoing hemodialysis (Gutiérrez et al., 2008). 
By contrast, observational studies of long-term 
hemodialysis patients showed that vitamin D treat-
ment has been associated with improved survival 
(Teng et al., 2005).  In addition, vitamin D use is 
associated with lower mortality in nondialysis pa-
tients with chronic kidney disease (Shoben et al., 
2008).  Therefore, the administration of 1,25(OH)2 
vitamin D3 has therapeutic value for patients with 
chronic kidney disease. 
 In this study, we examined the renoprotective 
effects of an ARB and/or 1,25(OH)2 vitamin D3 on 






Male spontaneously hypertensive rats of the Izumo 
strain were obtained from Japan SLC (Shizuoka, 
Japan), and maintained in a room at controlled tem-
perature of 24 ± 2˚C with a 12-h light-dark cycle. 
All experiments were carried out in accordance 
with the Animal Experimention Guidelines of Tot-
toti University.  
 Olmesartan was generously provided by 
Daiichi-Sankyo Pharmaceutical (Tokyo, Japan), 
was suspended in 0.5% of methylcellulose solution 
to a given concentration. Alfacalcidol was synthe-
sized in Chugai Pharmaceutical (Fuji-Gotemba, 
Japan), was dissolved in medium-chain triglyceride 
and diluted to given concentration.
 
Establishment of the model 
 
Anesthesia was performed by intraperitoneally in-
jecting pentobarbital (Dainippon Pharmaceutical, 
Osaka, Japan) at dose of 50 mg/kg.  The 6-week-
old spontaneously hypertensive rats undergone a 5/6 
nephrectomy, consisting of the surgical excision of 
approximately 2/3 of the renal cortex of the left kid-
ney.  One week later, the right kidney was removed. 
Then, the rats were divided into 4 experimental 
groups: 5/6Nx group, 5/6Nx rats (n = 8); Alf group, 
5/6Nx rats administered by gavage with 0.2 μg/kg/
day alfacalcidol (n = 8); Olm group, 5/6Nx rats ad-
ministered by gavage with 15 mg/kg/day olmesar-
tan, an ARB (n = 8); and Alf + Olm group, 5/6Nx 
rats administered by gavage with 0.2 μg/kg/day alfa-
calcidol and 15 mg/kg/day olmesartan (n = 8).  
 The dose of olmesartan was selected on the 
basis of an earlier study reporting that the rats would 
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Table 1.  Primer sequences
 Forward primer Reverse primer
TGF- 1 5'-CCTgCCCCTaCaTTTgga-3' 5'-TggTTgTagagggCaaggaC-3'
klotho 5'-CaagaagTTCaTaaTggaaagCTTaaa-3' 5'-aTgCggTgTaCCCaaTgaC-3'
-actin 5'-CTggCTCCTagCaCCaTga-3' 5'-TagagCCaCCaaTCCaCaCa-3'  
TGF, transforming growth factor.
exhibit comparable antihypertensive effects (Porteri 
et al., 2005).  The dose of alfacalcidol was examined 
previously in an ovariectomized rat model of osteo-
porosis for human (Shiraishi et al., 2000). 
 Drugs were administered once a day beginning 
1 week after the nephrectomy for 12 weeks.  Every 
4 weeks, we measured body weight, blood pressure, 
urinary volume and urinary protein of each groups. 
Blood pressure was measured in conscious rats by 
the tail-cuff method with a sphygmomanometer 
(Softron, Tokyo).  Urine was collected from individ-
ual rats housed in metabolic cages for 24 h.  At 12 
weeks after the administration, the rats were killed 
under pentobarbital anesthesia.  Blood was collected 
from their hearts, and those serum samples were 
frozen and stored at –80˚C. 
 Concentrations of serum creatinine, Ca, P, 
1,25(OH)2 vitamin D3, urinary protein and urinary 
creatinine were measured by routine laboratory 
methods.  The level of proteinuria excretion is af-
fected by the physique of animals.  So, we measured 
urinary protein levels using the ratio of urinary 
protein/creatinine, in which creatinine compensates 
the measurement of proteinuria.  Serum FGF23 
concentration was determined by using an FGF23 
enzyme-linked immunosorbent assay kit from Kai-
nos Laboratories (Tokyo).  The remnant kidneys 
were removed and fixed in 10% buffered formalin 
and embedded in paraffin for histological analysis. 
RNA extraction and reverse-transcription 
PCR analysis
 
Tissue samples were homogenized and total RNA 
was extracted by using the RNeasy Mini Kit 
(QIAGEN, Hilden, Germany).  RNA concentration 
was determined by measuring absorbance at 260 nm 
and the RNA quality was verified by electrophoresis 
on an ethidium-bromide-stained 1% agarose gel. 
About 2 μg of total RNA was reverse transcribed 
in a final volume of 11.5 μL containing 4 μL of 5 
× standard buffer, 2 μL of 0.1 M dithiothreitol, 1 
μL of SuperScriptII RNase H-reverse transcriptase 
(Life Technologies, Carlsbad, CA), 2 μL of 10 mM 
dNTPs (Promega, Madison, WI), 1 μL of 50 pmol/
μL Random Primers (Promega), 0.5 μL of 100 pmol/
μL Oligo (dt) 15 Primer (Promega) and 1 μL of 40 
units/μL Ribonuclease Inhibitor (Wako Pure Chemi-
cal Industries, Osaka, Japan).  The samples were in-
cubated at 37˚C for 60 min, and then 95˚C for 5 min 




To prepare a reverse transcribed sample, we mixed 
4.1 µL of PCR grade water, 1 µL of Universal 
PribeLibrary probe (Roche, Tokyo), 0.2 µL of 10-
μM Reverse primer, 2 µL of LightCycler TaqMan 
Master (Roche) and 2.5 µL of a cDNA sample, and 
used 10 µL of the mixture for quantitative real-time 
PCR.  The mRNA levels of transforming growth 
factor (TGF)- 1 and klotho genes were assessed 
by the real-time PCR assays, using -actin as an 
internal standard.  The forward and reverse primer 
sequences used for this study are shown in Table 
1.  The thermal cycler conditions were as follows: 
hold at 95˚C for 10 min, repeat 45 cycles of 95˚C 




Three micrometer-thick sections of formalin-fixed, 
paraffin-embedded kidneys were stained with pe-
riodic acid-Schiff and periodic acid-methenamine 
silver.  For calculating focal glomerular sclerosis, 
100 to 150 glomeruli from each stained specimen 
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were examined.  The degree of sclerosis in each 
glomerulus was subjectively graded on a scale of 
0 to 4 as follows:  Grade 0, no change; Grade 1, 
sclerotic area less than or equal to 1/4 of the glom-
erulus or the presence of distinct adhesion between 
the capillary tuft and Bowman’s capsule; Grade 2, 
sclerosis of 1/4 to 1/2 of the total glomerular area; 
Grade 3, sclerosis of 1/2 to 3/4 of the total glom-
erular area; Grade 4, sclerosis of more than 3/4 of 
the glomerulus.  The index of glomerular sclelosis 
(IGS) was calculated by using the following for-
mula (Kanazawa et al., 2002):  
 IGS = 
(1 × N1 + 2 × N2 + 3 × N3 + 4 × N4)
   (N0 + N1 + N2 + N3 + N4), 





Statistical significance of intergroup differences in 
quantitative data was assessed by Student’s t-test 
Fig. 1.  Courses of the mean SBP (a) and DBP (b) during 
the 12-week experimental period in the 4 groups of rats. 
Both pressures are significantly decreased at week 12 in 
groups of Alf, Olm and Alf + Olm when compared with 
in the 5/6Nx group.  5/6Nx, group of rats subjected to 5/6 
nephrectomy; Alf, group of 0.2 μg/kg/day alfacalcidol-
administered 5/6Nx rats; Olm, group of 15 mg/kg/day 
olmesartan-administered 5/6Nx rats; Alf + Olm, group of 
0.2 μg/kg/day alfacalcidol- and 15 mg/kg/day olmesartan-
administered 5/6Nx rats.  DPB, diastolic blood pressure; 
SBP, systolic blood pressure.
(Stat View for Windows; SAS Institute, Cary, NC). 







The systolic blood pressure of the rats during the 
12-week experimental period is shown in Fig. 1. 
The systolic blood pressure after nephrectomy was 
increased progressively throughout the experimen-
tal period in the 5/6Nx group.  After the initiation 
of treatment, the systolic blood pressures in the 
Alf, Olm and Alf + Olm groups were gradually 
decreased.  At the end of the 12-week administra-
tion period, each systolic blood pressure in the 
treated groups was significantly lower than that in 
the 5/6Nx group (233.0 ± 9.6 mmHg for the 5/6Nx 
group, 199.4 ± 18.6 mmHg for the Alf group, 
191.6 ± 14.2 mmHg for the Olm group, 136.0 ± 
19.9 mmHg for the Alf + Olm group).  The Alf 
+ Olm group showed significantly lower levels of 
the systolic blood pressur than any other group did 
at week 12.  In addition, we found a similar trend 
for diastolic blood pressure (Fig. 1).  At the end of 
the 12-week administration period, each diastolic 
blood pressure was also significantly lower than 
that in the 5/6Nx group (177.3 ± 8.8 mmHg for 
the 5/6Nx group, 140.6 ± 18.3 mmHg for the Alf 
group, 134.0 ± 12.1 mmHg for the Olm group, 94.1 




Figure 2 shows urinary protein excretion at every 
4 weeks for each group.  During the 12 weeks, uri-
nary protein excretion in the 5/6Nx group was in-
creased progressively throughout the experimental 
period.  In all treated groups, urinary protein excre-
tion was significantly lower than that in the 5/6Nx 
group at week 12.  Especially, urinary protein 
excretion in the Alf + Olm group was significantly 
decreased compared with that in the Alf group and 
Olm group. 
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Although olmesartan did not significantly decrease 
the serum creatinine level at week 12, the serum 
creatinine level in the Alf group was significantly 
Fig. 2.  Mean urinary protein levels at 0, 4, 8 and 12 weeks in the 4 groups.  Urinary protein excretion in the Alf + Olm 
group is significantly decreased compared with that in the 5/6Nx group, Alf group and Olm group at week 12.
Fig. 3.  Serum creatinine concentrations (a) and creatinine 
clearance levels (b) in the 4 groups at week 12.  The level 
of serum creatinine in the Alf + Olm group is significantly 
lower than the other groups.  The creatinine clearance in 
the Alf + Olm group is significantly improved in compari-
son with the 5/6Nx group.  Values are expressed as means 
± SD. 
lower than that in the 5/6Nx group (P < 0.01), but 
not significantly lower than that in the Olm group (P 
= 0.33).  The level of serum creatinine in the Alf + 
Olm group was significantly lower than that in the 
5/6Nx group (P < 0.01) and in 2 other alfacalcidol-
treated groups (P < 0.05) (Fig. 3a).  Figure 3b 
showed the creatinine clearance in the 4 groups of 
rats at week 12.  The creatinine clearance in the 
Alf + Olm group was significantly improved in 
comparison with the 5/6Nx group (P < 0.05).
 
Serum Ca, P and 1,25(OH)2 vitamin D3
 
Figure 4a shows serum Ca concentrations in the 4 
groups of rats at week 12.  The alfacalcidol-treated 
groups (Alf, Alf + Olm) had significantly higher 
Ca values than the 5/6Nx and Olm groups had 
(P < 0.01).  By contrast, the serum P values in the 
4 groups did not differ significantly (Fig. 4b).  We 
also examined the values of serum 1,25(OH)2 vita-
min D3 in the 4 groups at week 12.  The alfacalci-
dol-treated groups (Alf, Alf + Olm) had remarkably 
higher serum levels of 1,25(OH)2 vitamin D3 than 




Levels of serum FGF23 in the alfacalcidol-treated 
groups (Alf, Alf + Olm) at week 12 were signifi-
cantly higher than those in the 5/6Nx and Olm 
groups (P < 0.01) (Fig. 5).
54
T. Fukui et al.
Fig. 5.  Serum fibroblast growth factor 23 (FGF23) in the 4 
groups at week 12.  Levels of serum FGF23 in alfacalcidol-
treated groups at week 12 are significantly higher than those 
in non-treated groups. 
 
Histological findings in the kidney
 
Histological examination of the kidney revealed 
remarkably advanced glomerular sclerosis in the 
5/6Nx group at week 12.  Conversely, the Alf, Olm 
and Alf + Olm groups had bettered glomerular 
sclerosis.  Among the 3 groups, the Alf + Olm 
group markedly ameliorated glomerular sclerosis 
(Fig. 6a).
 The IGS in all treated groups was signifi-
cantly lower than that in the 5/6Nx group (P < 0.05 
for the Alf group, P < 0.05 for the Olm group and 
P < 0.01 for the Alf + Olm group).  The IGS in 
the Alf + Olm group was significantly lower than 
that in the Alf group (P < 0.05) and the Olm group 
(P < 0.01) (Fig. 6b).
 
mRNA quantification of TGF- 1 and klotho 
gene  
 
Figure 7 shows the mRNA levels of the TGF- 1 
gene and klotho gene in renal tissue.  The TGF- 1 
mRNA level in the 5/6Nx group was increased 
as compared with the levels in the other treated 
groups, significantly alleviated in the Alf and Alf 
+ Olm groups (P < 0.01 for the Alf group, P < 0.01 
for the Alf + Olm group), but not in the Olm group 
(Fig. 7a).
 The klotho mRNA levels of the alfacalcidol-
treated groups were increased in comparison with 
the level of the 5/6Nx group:  the increase was 
especially significant in the Alf + Olm group. 
Furthermore, in comparison between the 5/6Nx 
group and either of alfacalcidol-treated groups, 
the increase was significantly higher for the Alf 
+ Olm group than for the Alf group (P < 0.05 for 
the Alf + Olm group versus the 5/6Nx group, P < 
0.05 for the Alf + Olm group versus the Alf group) 
(Fig. 7b).
 
Fig. 4.  Serum concentrations of Ca (a), P (b) and 1,25(OH)2 
vitamin D3 (c).  Levels of Ca and 1,25(OH)2 vitamin D3 are 
significantly higher in alfacalcidol-treated groups than in 
non-treated groups.  Differences in P levels are not signifi-
cant among the 4 groups. 
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Fig. 6.  Levels of glomerular sclerosis examined at week 12. 
 
a: Histological examination of kidneys of rats in the 4 groups 
by periodic acid-Schiff staining.  The sclerosis remarkably 
advances in the 5/6Nx group, and improves in the Alf, Olm 
and Alf + Olm groups.  Especially, the sclerosis markedly 
ameliorates in the Alf + Olm group.  Bar = 200 µm. 
b: Levels of the index of glomerular sclerosis (IGS) in the 4 
groups at week 12.  All treated groups show significantly 
lower levels than the 5/6Nx group.  The Alf + Olm group 
show significantly lower level than the Alf and Olm groups. 
Fig. 7.  Expressions of mRNA for TGF- 1 and klotho genes in 
renal tissue.  
 
a: Expression of TGF- 1 mRNA.  TGF- 1 mRNA levels are 
significantly alleviated in the Alf and Alf + Olm groups, 
but not in the Olm group. 
b: Expression of klotho mRNA.  klotho mRNA levels in the 
treated groups are increased in comparison with the level in 
the 5/6Nx group.  The level is significantly increased in the 








In the present study, we demonstrated that the 
administration of alfacalcidol and/or olmesartan 
improved the CRF and up-regulated the klotho 
gene in the kidney.  In particular, the combination 
therapy of the 2 drugs provided the most effective 
renoprotection.  Spontaneously hypertensive rats 
have been used as a model for essential hyperten-
sion in humans, and 5/6Nx rats have commonly 
been used as an experimental model for CRF in 
humans.  In this study, we combined these 2 mod-
els, and prepared 5/6Nx spontaneously hyperten-
sive rats.  During the 12-week experimental period, 
blood pressure, urinary protein and glomerular 
sclerosis in the 5/6Nx spontaneously hypertensive 
rats increased progressively.  After 12 weeks, the 
glomerular sclerosis was remarkable.
 The renin-angiotensin system plays an impor-
tant role in the development of hypertension and the 
progression of CRF.  TGF- 1 has been shown to 
play a predominant role in mediating angiotensin II- 
induced extracellular matrix production and inhibits 
its degradation by increasing production of protein-
ase inhibitors in mesangial and tubulointerstitial 
cells (Border et al., 1992). Thus, TGF- 1 plays a 
central role in the development glomerular sclerosis 
and tubulointerstitial fibrosis.  In addition, continu-
ous administration of angiotensin II resulted in the 
development of CRF, and decreased klotho mRNA 
expression in the rat kidney (Mitani et al., 2002). 
In our previous study, we have shown that the 
group treated with olmesartan prevented the prog-
ress of CRF and the klotho mRNA downregulation 
in the 5/6Nx rats (Maeta et al., 2009).  In this study, 
the administration of olmesartan improved blood 
pressure, urinary protein, glomerular index of the 
kidney, and up-regulated the klotho mRNA.
 It is well known that klotho gene in the kidney 
of CRF patients was markedly reduced (Koh et al., 
2001).  Recently, the roles of klotho function have 
been evaluated.  Klotho protein exists in 2 forms: 
one is a secreted form that circulates in the blood, 
and the other is a transmembrane form expressed 
primarily in renal tubular cells (Kuro-o, 2009).  It 
has been revealed that the transmembrane form of 
klotho functions as a co-receptor for FGF23.
 FGF23 is secreted from osteocytes in re-
sponse to high blood levels of P and 1,25(OH)2 
vitamin D3 (Saito et al., 2005).  FGF23 reduces 1, 
25(OH)2 vitamin D3 by down-regulating the ex-
pression of the synthesized enzyme (Dusso et al., 
2005).  Thus, FGF23 induces a negative P balance 
by functioning as a phosphaturic hormone as well 
as a counter-regulatory hormone for 1,25(OH)2 
vitamin D3.  FGF23-deficient mice have hyper-
phospatemia and hypervitaminosis D associated 
with ectopic calcification.  Besides the predictable 
phenotypes, FGF23-deficient mice develop mul-
tiple aging-like phenotypes that are almost identi-
cal with those observed in klotho-deficient mice 
(Larsson et al., 2003).  These observations indicate 
that FGF23 and klotho may function in a common 
signal transduction pathway.  In our present study, 
levels of serum FGF23 in the groups treated with 
alfacalcidol (Alf group, Alf + Olm group) were sig-
nificantly higher than those in the 5/6Nx group and 
olmesartan alone treated group.
 1,25(OH)2 vitamin D3 plays an important role 
in controlling bone metabolism through the regula-
tion of Ca and P homeostasis.  1,25(OH)2 vitamin 
D3 deficiency is frequently recognized in patients 
with chronic kidney disease, in whom it is associ-
ated with increased mortality (Ravani et al., 2009). 
It was reported that 1,25(OH)2 vitamin D3 defi-
ciency has also been involved in the progression 
of renal failure (González et al., 2004).  Recently 
vitamin D analogues have been shown to have ben-
eficial effects in patients with diabetic nephropathy 
(de Zeeuw et al., 2010).  Several mechanisms could 
be involved in these renoprotective effects includ-
ing direct antiproteinuric effects thorough the 
protection of podocyte, interactions with the renin-
angiotensin system, and anti-inflammatory effects 
(Doorenbos et al., 2009).  In our present study, 
we also found that the alfacalcidol administration 
yielded renoprotective effects and improvement 
in blood pressure, proteinuria and the IGS and 
TGF- 1 gene expression.  These renoprotective ef-
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fects were the strongest in combination therapy of 
alfacalcidol and olmesartan.  There are also some 
reports of investigations on the effect of vitamin 
D on blood pressure (Kristal-Boneh et al., 1997; 
Witham et al., 2009; Judd et al., 2010).  Higher lev-
els of active vitamin D are associated with lower 
blood pressure.  Although the mechanism by which 
vitamin D may regulate blood pressure is unclear, 
it was suggested that vitamin D is negative regula-
tor of renin (Li et al., 2002). 
 It has been reported that renal injury was re-
duced in klotho-overexpressing transgenic mice, 
because of suppression of oxidative stress (Haruna 
et al., 2007).  In addition, klotho inhibited TGF- 1 
signaling and suppressed renal fibrosis (Doi et al., 
2011).  Moreover, the administration of 1,25(OH)2 
vitamin D3 induced klotho gene expression in the 
kidney (Tsujikawa et al., 2003).  The klotho mRNA 
level of the Alf + Olm group was significantly in-
creased compared with that of 5/6Nx group, such 
that suppression of klotho gene downregulation 
might attenuate the progression of renal damage.
 In the present study, we selected alfacalcidol 
as a vitamin D analogue.  As there have been no 
reports of alfacalcidol being used for uremic rats, 
the dose of alfacalcidol referred to in the previous 
reports of dosage in ovariectomized rats, osteo-
porosis model, was administered (Shiraishi et al., 
2000).  The values of serum Ca and 1,25(OH)2 
vitamin D3 of the groups treated with alfacalcidol 
(Alf group, Alf + Olm group) were found to be 
very high.  There is a possibility that hypercalce-
mia causes diuresis and natriuresis, which lead to 
dehydration and renal insufficiency (Shiraishi et 
al., 2003).  However, the values of serum creatinine 
and the IGS of alfacalcidol-treated groups was 
lower than those in the 5/6Nx group in the present 
study, so we thought that hypercalcemia did not 
cause renal injury.  In our study the serum FGF23 
levels in the groups treated with alfacalcidol (Alf 
group, Alf + Olm group) were significantly higher 
those in the 5/6Nx group and Olm group, despite 
the improvement of the IGS and klotho gene ex-
pression.  There was a therapeutic window for ac-
tive vitamin D therapy, whereby too high a dose 
could be harmful by raising FGF23 excessively, but 
lower doses might promote less elevation of FGF23 
(Isalova et al., 2009).  In the present study, the 
groups treated with alfacalcidol showed an increase 
in serum FGF23, but improvement of renal failure.
 In conclusion, the present study demonstrated 
that alfacalcidol and/or olmesartan exhibited a 
renoprotective effect, throughout the antihyperten-
sive effect, as well as upregulation of klotho gene 
expression in the kidney. 
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